# Anocca: Research, Södertälje, Sweden > Anocca: Anocca is a clinical-stage biopharmaceutical company based in Södertälje, Sweden, focused on developing precision T-cell receptor-engineered T cell... Source: https://millionrounds.com/startup/anocca (Millionrounds; every figure on the page links to its filing or article) Sweden · [Research startup](https://millionrounds.com/companies) # Anocca Anocca is a clinical-stage biopharmaceutical company based in Södertälje, Sweden, focused on developing precision T-cell receptor-engineered T cell (TCR-T) therapies for challengin Funding reported Last round: Undisclosed round Research Södertälje, Sweden Company summary - **Founded:** 2014 12 years old - **Team:** 130 51 to 200 people - **Funding reported:** 110.4M as listed, currency not stated - **Last round:** Undisclosed round May 2023 How sure we are - ✓ **Listed** We know it exists and what it does - 2 **Funding reported** A company dataset reports a raise - 3 **Observed** A filing or a dated announcement confirms a round No round for Anocca has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology) ## About Anocca Anocca is a clinical-stage biopharmaceutical company based in Södertälje, Sweden, focused on developing precision T-cell receptor-engineered T cell (TCR-T) therapies for challengin g diseases, particularly untreatable solid tumors. Founded in 2014, Anocca aims to decode T-cell immunity and create innovative T-cell immunotherapies. The company employs around 120-130 professionals, including scientists and engineers, in state-of-the-art facilities. Anocca's primary offerings include a library of TCR-T cell therapies, with over 40 assets targeting various cancer types. Its most advanced therapy is aimed at the KRAS G12V mutation in pancreatic cancer, currently entering a Phase 1/2a clinical trial. In addition to oncology, Anocca is exploring applications for infectious and autoimmune diseases, as well as developing vaccination strategies that utilize T-cell immunity. The company serves healthcare providers and patients, particularly those facing the most difficult-to-treat cancers, and is expanding its reach with an international focus on clinical trials in Europe. ## What company datasets say Anocca raised Funding, as reported Reported in all **110.4M** in the source's currency Rounds **3** Last round **Undisclosed round** Last round size **46M** Last round date **May 2023** Investors listed **9** ## Founders and team From Anocca's own website: 1 founder, 29 on the team. **Reagan Jarvis** Chief Executive Officer, Scientific founder - **Hugh Salter** Chief Scientific Officer - **Jacob Michlewicz** Chief Finance Officer - **Luke Pase** Chief Technology Officer - **Mark Farmery** Chief Development Officer - **Ryan Hill** Chief Information Officer - **Viktor Arnkil** Chief Operating Officer - **Zahid Bashir** Chief Medical Officer - **Arjudeb Mukherjee** VP Strategy & Corporate Development - **Mattias Persson** Head of Engineering - **Niclas Sandberg** Head of Quality Control - **Niklas Sjökvist** Head of Production - **Zach Chia** VP Strategy & Business Development - **Alejandra Frasch** Senior Scientist - **Amu Wang** Director of Clinical Operations - **Anette Brass** Principal Scientist - **Athina Totomi** Platform Project Manager - **Charlotte Gustafsson** Senior Scientist - **Daniela Casarrubea** Principal Scientist And 11 more on the team. ## On a portfolio page Investors who name them - [Blue](https://millionrounds.com/fund/blue-2) Each firm lists Anocca on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source. ## The company, in detail What they build Known for autoimmune disease research engineered t-cells targeted cell therapies health care tcr gene assembly tcr evolution technology tcr gene reconstitution system autoimmunity personalized tcr therapies tcr library for diverse cancers precision t-cell therapies tcr affinity maturation tcr gene editing with crispr engineered human cells biotechnologies biotechnology research Built with from their website Priority Hints React Cvent Event Marketing & Management WordPress.org HSTS Microsoft Exchange TypeScript Microsoft 365 Cvent MySQL +8 more Outlook Django Cvent Registration Zoom Meetings Microsoft 365 Apps & Services Microsoft Windows PHP Viewport Meta - **Sector:** Research - **Industry code:** NAICS 541714, 325414, SIC 2834, 8731 - **Region:** Stockholms laen - **Revenue:** 5M a year, as listed - **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/anocca) ## Research in Sweden Startups like it - [**SmartCella Holding AB** Botkyrka · founded 2014](https://millionrounds.com/startup/smartcella-holding-ab) - [**Navinci** Uppsala · founded 2004](https://millionrounds.com/startup/navinci) - [**AnaCardio** Gothenburg · founded 2017](https://millionrounds.com/startup/anacardio) - [**Akiram Therapeutics** Uppsala · founded 2021](https://millionrounds.com/startup/akiram-therapeutics) - [**Strike Pharma AB** Uppsala · founded 2020](https://millionrounds.com/startup/strike-pharma-ab) - [**Umecrine Cognition AB** Gothenburg · founded 2000](https://millionrounds.com/startup/umecrine-cognition-ab) - [**Ljusgårda AB** Tibro · founded 2017](https://millionrounds.com/startup/ljusg-rda-ab) - [**Empros Pharma** Gothenburg · founded 2014](https://millionrounds.com/startup/empros-pharma) ## Is this your company? Add your raise, your deck and your story, and put Anocca in front of investors. Or tell us what we have wrong. [List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)